At Medtronic, we believe everyone should have access to quality, affordable healthcare. We also know that we lack the appropriate innovations to reach billions of patients who do not have access to our therapies and services. Designing innovative healthcare-access solutions in resource-limited settings requires a fundamentally different approach.
Formalized in 2016, Medtronic Labs is a distinct business within Medtronic that maximizes social impact alongside financial sustainability. Medtronic Labs designs healthcare delivery service models with and for underserved communities that integrate digital and product technologies across the patient care continuum. To amplify our impact and reach scale, we partner with local tech entrepreneurs, healthcare providers, NGOs, governments, and other stakeholders.
Addresses the spread of chronic ear infections and associated hearing loss through awareness, diagnosis, and treatment in underserved populations in India.
End-to-end model of care for hypertension and diabetes screening and management that improves disease awareness, reduces the burden of disease, and improves the efficiency of managing hypertension and diabetes for both patients and clinicians in Kenya and Ghana.
Over the past nine months, the Medtronic Labs team has been working with communities in India to create the future of chronic disease care. Launching in 2019, the Prerna pilot is a comprehensive healthcare delivery model for people living with, or at risk for, type II diabetes, hypertension, and co-morbid cardiovascular diseases in India. Our model integrates social and clinical interventions in a group-based setting, close to home. Once enrolled, a Prerna patient receives everything they need to live with their condition for the long-term — point of care lab testing, doctor visits, medication, education, and behavior coaching — all in the comfort of their community.
Launched in September 2018, Maisha Mapya brings the Empower Health model of care into the maternal health ecosystem. This pilot of 150 pregnant women in Kenya will assess the viability of this model of care in this patient segment. Maisha Mapya aims to provide patients with ongoing visibility to their health status, increase access to education and community group support, increase timely referrals to care, and decrease the likelihood for hypertension-related complications during the antenatal and postpartum time periods for women diagnosed with hypertension in pregnancy. The pilot aims to conclude December 2019.